Comparative Pharmacology
Head-to-head clinical analysis: AGGRENOX versus PLETAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGGRENOX versus PLETAL.
AGGRENOX vs PLETAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aggrenox is a combination of dipyridamole and aspirin. Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells, and erythrocytes, leading to increased extracellular adenosine which stimulates platelet adenylate cyclase, increasing cAMP levels and inhibiting platelet aggregation. Aspirin irreversibly acetylates cyclooxygenase-1 (COX-1), inhibiting thromboxane A2 synthesis, thereby reducing platelet aggregation.
Cilostazol inhibits phosphodiesterase III (PDE3), increasing cAMP levels in platelets and vascular smooth muscle, leading to platelet inhibition and vasodilation.
One capsule (dipyridamole 200 mg plus aspirin 25 mg) orally twice daily.
100 mg orally twice daily, administered at least 30 minutes before or 2 hours after meals.
None Documented
None Documented
Aspirin: 15-20 minutes for parent drug; salicylate terminal half-life 3-6 hours (dose-dependent). Dipyridamole: terminal half-life approximately 10-12 hours. Clinical context: Typical twice-daily dosing maintains therapeutic antiplatelet effect.
Terminal half-life of cilostazol is approximately 11-13 hours; for active metabolites 3,4-dehydro-cilostazol (about 4-6 times more active) half-life is similar. Steady state achieved within a few days.
Aspirin: renal elimination of salicylate and metabolites (primarily salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, and gentisic acid) accounts for >90% of a dose. Dipyridamole: primarily biliary excretion as glucuronide conjugates (enteric recycling); renal excretion accounts for <5% of unchanged drug.
Renal (approximately 77% as metabolites, <1% unchanged); fecal (approximately 18%)
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent